Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-arm Study of JWCAR239 in the Treatment of Relapse / Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

NCT07024147 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07024147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07024147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-arm Study of JWCAR239 in the Treatment of Relapse / Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 1, 2025
Completion date
July 1, 2030
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma, follicular lymphoma, large b cell diffuse lymphoma, mantle cell lymphoma (mcl), marginal zone b cell lymphoma